View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Henrik Bartnes
  • Martin Melbye
ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Henrik Bartnes
  • Martin Melbye
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Magnus Andersson
  • Patrik Brattelius
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Magnus Andersson
  • Patrik Brattelius
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Magnus Andersson
  • Patrik Brattelius
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Henrik Bartnes
  • Martin Melbye
Jesper Ingildsen
  • Jesper Ingildsen

Embla Medical (Buy, TP: DKK35.50) - Better start to the year than expe...

The c4% organic growth in Q1 was better than feared (consensus c3%), and with growth momentum likely to pick up in the coming quarters, we expect the company to reach c6% (previously c5%) in 2025. It kept its 2025 EBITDA margin guidance despite steep tariff exposure, citing high uncertainty and mitigation efforts. We reiterate our BUY with a raised target price of DKK35.5 (34).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Johannes Grunselius
  • Johannes Grunselius

UPM (Buy, TP: EUR36.00) - Solid entry points into quality

Following the solid Q1 report that was supported by the low-cost pulp operations in Uruguay, we have kept our optimistic 2025–2027e earnings, translating into highly attractive valuation multiples largely unchanged. With heavily reduced capex set for the coming years, we also still forecast strong cash flows, leaving the balance sheet overcapitalised. With this backdrop, we believe UPM will continue to pursue buybacks on top of compelling dividends in most feasible scenarios. We reiterate our BU...

ABGSC Pulp & Paper Research ... (+4)
  • ABGSC Pulp & Paper Research
  • Ali Shemmari
  • Henrik Bartnes
  • Martin Melbye
Nicolas McBeath
  • Nicolas McBeath

Nordnet (Buy, TP: SEK293.00) - Firing on all cylinders

Both Q1 revenues and PTP were record-high (both up 11% YOY), powered by strong brokerage income and resilient NII despite falling rates. Activity looks elevated going into Q2, and we see upside potential to NII consensus estimates. The total return profile remains attractive on our expectation of c10% long-term EPS growth and a c5% total yield. We reiterate our BUY and have raised our target price to SEK293 (274).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch